\begin{tabular}{p{6cm}cc}
& \multicolumn{2}{c}{\textbf{England Prevalence (\%)  }} \\[0.5ex] &
  \emph{OpenSafely Sample} & \emph{This Study} \\[2ex]
Age 18-39 & 34.4 & \num{$$uk_age_18_40$$} \\[0.25ex]
Age 40-49 & 16.5 & \num{$$uk_age_40_50$$} \\[0.25ex]
Age 50-59 & 17.6 & \num{$$uk_age_50_60$$}\\[0.25ex]
Age 60-69 & 13.8 & \num{$$uk_age_60_70$$}\\[0.25ex]
Age 70-79 & 11.2 & \num{$$uk_age_70_80$$}\\[0.25ex]
Age 80+ & 6.5 & \num{$$uk_age_80$$} \\[0.25ex]
Male & 49.9 & \num{$$male$$} \\[0.25ex]
Diabetes (Controlled) & 6.0 & \num{$$uk_prev_diabetes_contr$$} \\[0.25ex]
Diabetes (Uncontrolled) & 2.8 & \num{$$uk_prev_diabetes_uncontr$$} \\[0.25ex]
Hypertension & 34.2 & \num{$$uk_prev_hypertension_both$$} \\[0.25ex]
Obese (class I \& II) & 19.1 & \num{$$uk_prev_obese_1_2$$} \\[0.25ex]
Obese (class III) & 2.7 & \num{$$uk_prev_obese_3$$} \\[0.25ex]
Chronic Heart Disease & 6.7 & \num{$$uk_gbd_chronic_heart_dz_mu$$} \\[0.25ex]
Chronic Respiratory Disease & 4.1 & \num{$$uk_prev_chronic_resp_dz$$}
\\[0.25ex]
Asthma & 1.7 & \num{$$uk_gbd_asthma_ocs_mu$$} \\[0.25ex]
Kidney Disease & 6.3 & \num{$$uk_gbd_kidney_dz_mu$$} \\[0.25ex]
Chronic Liver Disease & 0.7 & \num{$$uk_gbd_liver_dz_mu$$} \\[0.25ex]
Haematological Cancer & 0.1 & \num{$$uk_gbd_haem_malig_1_mu$$}\\[0.25ex]
Non-haematological Cancer & 0.5 & \num{$$uk_gbd_cancer_non_haem_1_mu$$} \\[0.25ex]
Stroke, Dementia & 2.1 & \num{$$uk_gbd_stroke_dementia_mu$$} \\[0.25ex]
Other Neurological Condition & 1.0 & \num{$$uk_gbd_neuro_other_mu$$} \\[0.25ex]
Psoriasis, Rheumatoid & 5.1 & \num{$$uk_gbd_autoimmune_dz_mu$$} \\[0.25ex]
Other Immunosuppressive Conditions & 1.6 & \num{$$uk_gbd_immuno_other_dz_mu$$} \\[0.25ex]
\end{tabular}
